PHAT Phathom Pharmaceuticals (PHAT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001783183
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
80
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $86.6K priced
Phathom Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Phathom Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 5, 2025.
- The trade is 1.1% of the 47,407 shares held after it.
- No other insider sold within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Breedlove Robert Charles sold about $7.1K of PHAT on Nov 3, 2025; 80 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 16, 2025.
- The trade is 1.0% of the 47,931 shares held after it.
- No other insider sold within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Breedlove Robert Charles sold about $5.6K of PHAT on Sep 5, 2025; 80 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.5% of the 48,392 shares held after it.
- No other insider sold within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Breedlove Robert Charles sold about $14.1K of PHAT on Jul 16, 2025; 80 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 14, 2025.
- +215.0% median (+213.9% mean) 90-day return after 4 previous buys.
- The trade is 6.4% of the 59,403 shares held after it.
- 1 other insider bought within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Topper James N bought about $14.6K of PHAT on May 21, 2025; 1 other insider bought within 30 days and 80 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on May 13, 2025.
- +210.6% median (+212.1% mean) 90-day return after 3 previous buys.
- The trade is 11.3% of the 55,623 shares held after it.
- 1 other insider bought within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Topper James N bought about $20.9K of PHAT on May 14, 2025; 1 other insider bought within 30 days and 80 funds added in the latest 13F quarter.64 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
80 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
+216.9% year over year
more than 90% of Pharma & Biotech
Margin
-126.3% net margin
below 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
15.5% of the float short (float per yahoo 2026-10-26) · 7.4 days to cover · settled 2026-09-30
more than 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PHAT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-56.4%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PHAT: institutional holders (13F)
13F holdings, latest reported quarter
12,466,489 sh
$135.3M
7,464,572 sh
$81.0M
4,525,129 sh
$49.1M
4,029,731 sh
$43.7M
3,496,808 sh
$37.9M
Congress trades in PHAT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PHAT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PHAT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$2.7M position · as of 2026-06-30
3.5%
Wasatch Micro Cap Fund
$8.8M position · as of 2026-06-30
1.3%
Virtus Biotech Etf
$1.1M position · as of 2026-07-31
1.2%
AMG GW&K Small Cap Growth Fund
$2.3M position · as of 2026-07-31
1.1%
AMG GW&K Small/Mid Cap Growth Fund
$474.8K position · as of 2026-07-31
1.1%
Wasatch Ultra Growth Fund
$5.0M position · as of 2026-06-30
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
7
Phase 1
0 active
2
Phase 2
1 active
2
Phase 3
1 active
1
Not applicable
1 active
What changed recently
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for
2026-10-08 · Not Yet Recruiting → Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$3.6M
$3.8M
$1.5M
-28%
n/a
2023
$3.4M
$2.5M
$2.0M
-19%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 80 funds added last quarter. Each figure is a federal filing, dated the day it went public.
PHAT financials
Revenue growth
+216.9%
XBRL, annual
Net margin
-126.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$239.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PHAT
| FY Dec 2025 | $175.1M |
| FY Dec 2024 | $55.3M |
| FY Dec 2023 | $682.0K |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $74.3M |
| Mar 2026 | $58.3M |
| Dec 2025 | $57.6M |
| Sep 2025 | $49.5M |
| Jun 2025 | $39.5M |
| Mar 2025 | $28.5M |
| Dec 2024 | $29.7M |
| Sep 2024 | $16.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+50.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PHAT
| FY Dec 2025 | -0.1% |
| FY Dec 2024 | -0.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -23.7% |
| Mar 2026 | -52.1% |
| Dec 2025 | +347.1% |
| Sep 2025 | -60.5% |
| Jun 2025 | -191.9% |
| Mar 2025 | -330.7% |
| Dec 2024 | +874.9% |
| Sep 2024 | -523.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$36.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PHAT
| FY Dec 2025 | -$167.0M |
| FY Dec 2024 | -$266.9M |
| FY Dec 2023 | -$139.2M |
| FY Dec 2022 | -$147.6M |
| FY Dec 2021 | -$148.8M |
| Jun 2026 | -$2.0M |
| Mar 2026 | -$15.7M |
| Dec 2025 | -$5.1M |
| Sep 2025 | -$14.1M |
| Jun 2025 | -$62.8M |
| Mar 2025 | -$84.9M |
| Dec 2024 | -$63.5M |
| Sep 2024 | -$63.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity PHAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.39x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.22x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt PHAT
| FY Dec 2025 | -0.80x |
| FY Dec 2024 | -1.32x |
| FY Dec 2023 | -1.00x |
| FY Dec 2022 | -1.54x |
| FY Dec 2021 | -1.48x |
| Jun 2026 | -0.22x |
| Mar 2026 | -0.60x |
| Dec 2025 | -0.80x |
| Sep 2025 | -1.09x |
| Jun 2025 | -1.34x |
| Mar 2025 | -1.39x |
| Dec 2024 | -1.32x |
| Sep 2024 | -1.41x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity PHAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -108.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+42.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PHAT
| FY Dec 2025 | -0.1% |
| FY Dec 2024 | -0.1% |
| FY Dec 2023 | -0.1% |
| FY Dec 2022 | -111.6% |
| FY Dec 2021 | -59.4% |
| Jun 2026 | +42.3% |
| Mar 2026 | +21.3% |
| Dec 2025 | -0.1% |
| Sep 2025 | +19.0% |
| Jun 2025 | +1.3% |
| Mar 2025 | -3.6% |
| Dec 2024 | -0.1% |
| Sep 2024 | -44.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PHAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-24.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PHAT
| FY Dec 2025 | -76.2% |
| FY Dec 2024 | -83.1% |
| FY Dec 2023 | -65.1% |
| FY Dec 2022 | -111.6% |
| FY Dec 2021 | -65.9% |
| Jun 2026 | -24.5% |
| Mar 2026 | -48.3% |
| Dec 2025 | -76.2% |
| Sep 2025 | -91.0% |
| Jun 2025 | -124.9% |
| Mar 2025 | -107.4% |
| Dec 2024 | -83.1% |
| Sep 2024 | -107.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PHAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$462.7M
market value at close 2026-10-26 on 2026-07-27 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value PHAT
| FY Dec 2025 | $1.3B |
| FY Dec 2024 | $459.4M |
| FY Dec 2023 | $279.2M |
| FY Dec 2022 | $406.9M |
| FY Dec 2021 | $534.7M |
| Jun 2026 | $847.5M |
| Mar 2026 | $858.2M |
| Dec 2025 | $1.3B |
| Sep 2025 | $906.9M |
| Jun 2025 | $725.1M |
| Mar 2025 | $427.6M |
| Dec 2024 | $459.4M |
| Sep 2024 | $918.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-7.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield PHAT
| FY Dec 2025 | -14.2% |
| FY Dec 2024 | -48.1% |
| FY Dec 2023 | -26.6% |
| FY Dec 2022 | -31.6% |
| FY Dec 2021 | -24.1% |
| Jun 2026 | -4.3% |
| Mar 2026 | -11.2% |
| Dec 2025 | -14.2% |
| Sep 2025 | -27.0% |
| Jun 2025 | -41.1% |
| Mar 2025 | -64.8% |
| Dec 2024 | -48.1% |
| Sep 2024 | -23.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PHAT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $175.1M | $55.3M | $682.0K | $0 |
| Gross profit | $152.5M | $47.3M | $515.0K | $0 |
| Operating income | -$160.0M | -$277.5M | -$167.3M | -$172.4M |
| Net income | -$221.2K | -$334.3K | -$201.6K | -$197.7M |
| EPS (diluted) | n/a | n/a | n/a | -5.05 |
| Operating cash flow | -$166.8M | -$266.8M | -$137.6M | -$146.5M |
| Cash | $130.0M | $297.3M | $381.4M | $155.4M |
| Long-term debt | $209.1M | $201.4M | $137.8M | $95.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
PHAT Stock Sonar score 5/7 axes
Find similar shapesComparePHAT ranks highest on growth (90th percentile) and profitability (83rd), and lowest on risk and compliance (17th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
